Yttrium-90 radioembolization using TheraSphere® in the management of primary and secondary liver tumors

A. Riaz, R. J. Lewandowski, L. Kulik, R. Salem*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

Locoregional therapies, such as transarterial chemoembolization, radioembolization and thermal ablation (e.g., radiofrequency ablation) are establishing their roles in the management of liver malignancies. With yYttrium-90 radioembolization therapy (90Y) radionuclide labeled microspheres are injected into the tumor feeding artery. This allows the delivery of a high radioactive dose to the tumor with minimal toxicity to normal tissues. 90Y has demonstrated to be safe and effective in the management of liver tumors. Authors present a review of the literature available for the use of TheraSphere® for radioembolization in the management of liver tumors.

Original languageEnglish (US)
Pages (from-to)311-316
Number of pages6
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume53
Issue number3
StatePublished - Jun 1 2009

Keywords

  • Carcinoma, hepatocellular
  • Liver neoplasms
  • Operative
  • Surgical procedures

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Yttrium-90 radioembolization using TheraSphere® in the management of primary and secondary liver tumors'. Together they form a unique fingerprint.

Cite this